Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 17/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 11/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20321903 | 0.86 | ADRB2 (0.54) | ADRB2ADRB1 | |
| SCHEMBL12594506 | 0.83 | ADRB2 (0.54) | ADRB2ADRB1MAOAMAOB | |
| SCHEMBL561768 | 0.82 | ADRB2 (0.53) | ADRB2ADRB1MAOAMAOB | |
| SCHEMBL563580 | 0.82 | ADRB2 (0.42) | ADRB2ADRB1MAOAMAOBCREBBP | |
| SCHEMBL29749604 | 0.82 | ADRB2 (0.42) | ADRB2ADRB1MAOAMAOBCREBBP | |
| SCHEMBL19350700 | 0.79 | ADRB2 (0.62) | ADRB2ADRB1 | |
| SCHEMBL18227271 | 0.77 | ADRB2 (0.49) | ADRB2ADRB1 | |
| SCHEMBL564397 | 0.77 | ADRB1 (0.79) | ADRB2ADRB1 | |
| SCHEMBL564845 | 0.77 | MAOA (0.46) | ADRB2ADRB1MAOAMAOBCREBBP | |
| SCHEMBL560342 | 0.77 | MAOB (0.48) | ADRB2ADRB1MAOAMAOBCREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1794154-B1 | HETEROARYL COMPOUNDS FOR USE AS BETAMIMETICS IN THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2013-02-27 | — | — | EP | disclosed |
| US-7939658-B2 | Enantiomeric pure beta agonists, manufacturing and use as a medicaments thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-10 | — | — | US | disclosed |
| US-20100297028-A1 | MEDICAMENT COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20090306068-A1 | NOVEL ENANTIOMERIC PURE BETA AGONISTS, MANUFACTURING AND USE AS A MEDICAMENTS THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-10 | — | — | US | disclosed |
| US-7534789-B2 | Enantiomeric pure β agonists, manufacturing and use as a medicament thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-19 | — | — | US | disclosed |
| EP-1996581-A1 | NOVEL ENANTIOMERICALLY PURE BETA-AGONISTS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-03 | — | — | EP | disclosed |
| EP-1986644-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES | Boehringer Ingelheim International GmbH (DE) | 2008-11-05 | — | — | EP | disclosed |
| US-7429583-B2 | Betamimetics for the treatment of respiratory complaints | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-09-30 | — | — | US | disclosed |
| WO-2007104772-A9 | NOVEL ENANTIOMERICALLY PURE BETA-AGONISTS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2007-11-22 | — | — | WO | disclosed |
| US-20070249595-A1 | Novel Enantiomeric Pure Beta Agonists, Manufacturing and Use as a Medicament Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-25 | — | — | US | disclosed |
| WO-2007104772-A1 | NOVEL ENANTIOMERICALLY PURE BETA-AGONISTS, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-20 | — | — | WO | disclosed |
| US-20070203125-A1 | Medicament Combinations for the Treatment of Respiratory Diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-30 | — | — | US | disclosed |
| WO-2007093608-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF RESPIRATORY TRACT DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-23 | — | — | WO | disclosed |
| EP-1794154-A1 | HETEROARYL COMPOUNDS FOR USE AS BETAMIMETICS IN THE TREATMENT OF RESPIRATORY DISEASES | Boehringer Ingelheim International GmbH (DE) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006032627-A1 | HETEROARYL COMPOUNDS FOR USE AS BETAMIMETICS IN THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063817-A1 | New betamimetics for the treatment of respiratory complaints | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063817-A1 | New betamimetics for the treatment of respiratory complaints | CHRM1, ADRB1, ADRA1B | ADRB2 4/4885ADRB1 2/4885MAOA 209/4885 |
| US-20090306068-A1 | NOVEL ENANTIOMERIC PURE BETA AGONISTS, MANUFACTURING AND USE AS A MEDICAMENTS THEREOF | ADRB1, ADRB2, ADRA1B | ADRB2 2/4885ADRB1 1/4885MAOA 376/4885 |
| US-20070249595-A1 | Novel Enantiomeric Pure Beta Agonists, Manufacturing and Use as a Medicament Thereof | ADRB1, ADRA1B, ADRA2B | ADRB2 4/4885ADRB1 1/4885MAOA 313/4885 |
| US-20070203125-A1 | Medicament Combinations for the Treatment of Respiratory Diseases | CHRM1, CHRM2, MTNR1B | ADRB2 12/4885ADRB1 35/4885MAOA 293/4885 |
| US-20100297028-A1 | MEDICAMENT COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES | CHRM1, CHRM2, MTNR1B | ADRB2 12/4885ADRB1 35/4885MAOA 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.